Nexara Health — Health Canada Drug Establishment Licence #3-002896

Neostigmine Methylsulfate — products, DINs, and Canadian availability

This page lists Health Canada–registered pharmaceutical products whose active ingredient list includes Neostigmine Methylsulfate. We track 26 distinct Drug Identification Numbers (DINs) for this molecule, of which 6 are currently in marketed status. Across those registrations there are 11 manufacturers or marketing authorization holders, 2 dosage forms, and 5 distinct strength presentations.

Procurement teams normally arrive here for one of three reasons: a specific brand is unavailable and an equivalent registration is needed; a clinical protocol requires a comparator containing Neostigmine Methylsulfate in a defined strength; or a pharmacy needs to know which manufacturers still hold an active Canadian registration before committing to a substitution. The table below answers the first question directly. For the second and third, Nexara Health can confirm live availability, remaining shelf life, and landed cost from Canadian stock or from any of more than 40 regulated international source markets.

Registration status is not the same as availability. A product can hold marketed status in the Drug Product Database and still be on allocation, discontinued by the holder, or unavailable in the pack size a hospital needs. Where a Neostigmine Methylsulfate product is in shortage, our Canadian drug shortage tracker carries the reported status, the reason where the manufacturer has published one, and the marketed alternatives sharing the same active ingredient.

Dosage forms and strengths recorded for Neostigmine Methylsulfate

Dosage forms: Liquid, Solution. Strengths: .5 MG, 1 MG, 0.5 MG, 2.5 MG, 2 MG.

Manufacturers and marketing authorization holders

DAVID BULL LABORATORIES (PTY) LTD., FRESENIUS KABI CANADA LTD, SANDOZ CANADA INCORPORATED, STERIMAX INC, MARCAN PHARMACEUTICALS INC, JUNO PHARMACEUTICALS CORP., JAMP PHARMA CORPORATION, OMEGA LABORATORIES LIMITED, PHARMASCIENCE INC, ICN CANADA LTD., DISTRIVET INC..

Registered products containing Neostigmine Methylsulfate

DINProductManufacturerStrengthDosage formStatus
01904183NEOSTIGMINE METHYLSULFATE INJ 0.5MG/ML USPDAVID BULL LABORATORIES (PTY) LTD..5 MGLiquidCancelled Post Market
01914588NEOSTIGMINE METHYLSULFATE INJ 1MG/ML USPDAVID BULL LABORATORIES (PTY) LTD.1 MGLiquidCancelled Post Market
02243103NEOSTIGMINE METHYLSULFATE INJECTIONFRESENIUS KABI CANADA LTD1 MGLiquidCancelled Pre Market
02243104NEOSTIGMINE METHYLSULFATE INJECTIONFRESENIUS KABI CANADA LTD0.5 MGLiquidCancelled Pre Market
02385201NEOSTIGMINE METHYLSULFATE INJECTION SDZSANDOZ CANADA INCORPORATED0.5 MGSolutionCancelled Pre Market
02385228NEOSTIGMINE METHYLSULFATE INJECTION SDZSANDOZ CANADA INCORPORATED2.5 MGSolutionCancelled Pre Market
00885282NEOSTIGMINE METHYLSULFATE INJECTION USPSANDOZ CANADA INCORPORATED1 MGLiquidCancelled Post Market
01915436NEOSTIGMINE METHYLSULFATE INJECTION USPSANDOZ CANADA INCORPORATED2.5 MGSolutionCancelled Post Market
02497786NEOSTIGMINE METHYLSULFATE INJECTION USPSTERIMAX INC1 MGSolutionApproved
02475480NEOSTIGMINE METHYLSULFATE INJECTION USPMARCAN PHARMACEUTICALS INC0.5 MGSolutionMarketed
02475499NEOSTIGMINE METHYLSULFATE INJECTION USPMARCAN PHARMACEUTICALS INC1 MGSolutionMarketed
02497778NEOSTIGMINE METHYLSULFATE INJECTION USPSTERIMAX INC0.5 MGSolutionApproved
00874957NEOSTIGMINE METHYLSULFATE INJECTION USPSANDOZ CANADA INCORPORATED0.5 MGSolutionCancelled Post Market
02546183NEOSTIGMINE METHYLSULFATE INJECTION, USPJUNO PHARMACEUTICALS CORP.1 MGSolutionCancelled Pre Market
02537516NEOSTIGMINE METHYLSULFATE INJECTION, USPJAMP PHARMA CORPORATION0.5 MGSolutionMarketed
02546175NEOSTIGMINE METHYLSULFATE INJECTION, USPJUNO PHARMACEUTICALS CORP.0.5 MGSolutionCancelled Pre Market
02546191NEOSTIGMINE METHYLSULFATE INJECTION, USPJUNO PHARMACEUTICALS CORP.2.5 MGSolutionCancelled Pre Market
02230592NEOSTIGMINE OMEGAOMEGA LABORATORIES LIMITED1 MGLiquidMarketed
02230593NEOSTIGMINE OMEGAOMEGA LABORATORIES LIMITED0.5 MGLiquidMarketed
02387166NEOSTIGMINE OMEGAOMEGA LABORATORIES LIMITED2.5 MGSolutionMarketed
00868906PMS-NEOSTIGMINE METHYLSULFATE INJ 0.5MG/MLPHARMASCIENCE INC.5 MGLiquidCancelled Post Market
00868930PMS-NEOSTIGMINE METHYLSULFATE INJ 1MG/MLPHARMASCIENCE INC1 MGLiquidCancelled Post Market
00869929PROSTIGMIN INJ 1:1000 USPICN CANADA LTD.1 MGLiquidCancelled Post Market
00869910PROSTIGMIN INJ 1:2000 USPICN CANADA LTD..5 MGLiquidCancelled Post Market
00869937PROSTIGMIN INJ 1:400 USPICN CANADA LTD.2.5 MGSolutionCancelled Post Market
00564508STIMULINE INJ 2MG/MLDISTRIVET INC.2 MGLiquidCancelled Post Market

Sourcing Neostigmine Methylsulfate through a licensed wholesaler

Nexara Health imports and distributes under Health Canada Drug Establishment Licence #3-002896. For Neostigmine Methylsulfate we can quote Canadian-marketed presentations, equivalent registrations from the EU, UK, US, Switzerland, Australia, and Japan where the Canadian presentation is unavailable, and comparator-grade supply with Certificate of Analysis, batch and expiry records, and full chain of custody for clinical trial use. Cold-chain presentations ship under GDP conditions with continuous temperature monitoring.

Request a quote

Nexara Health is a Health Canada–licensed pharmaceutical wholesaler (DEL #3-002896) based in Winnipeg, Manitoba, supplying hospitals, pharmacies, clinics, CROs, and trial sponsors across Canada. Send us the product, strength, presentation, and quantity for Neostigmine Methylsulfate and we will come back with availability, source market, lead time, and landed cost — usually within 24 hours.

Request a sourcing quote or call +1 (431) 588-9055.

Related pages